MedTrace Logo

Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid

NCT00838877 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2009-10-23

No results posted yet for this study

Summary

The study is carried out in order to investigate if \[18F\]AZD4694, compared to \[11C\]AZD2184, is a suitable PET ligand for in vivo imaging of Aβ amyloid depositions in the human brain. In the study the two PET ligands will be examined in both healthy volunteers and patients with Alzheimer's Disease. A whole body dosimetry scanning will be performed in 6 healthy volunteers to obtain human data to estimate a safe dose.

Conditions

Interventions

DRUG

radioligand [18F]AZD4694

single dose of iv. admin. 1-2 times per subject

DRUG

radioligand [11C]AZD2184

single dose of iv admin. 1 time per subject

Sponsors & Collaborators

Principal Investigators

  • Maria E Jönhagen · Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden

  • Ingemar Bylesjö · AstraZeneca Clinical Pharmacology Unit, Stockholm

  • Per Julin · AstraZeneca R&D, Södertälje, Sweden

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Completion
2009-10-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00838877 on ClinicalTrials.gov